|
|
 |
|
Viewing report
|
|
|
|
Infectious Diseases Drugs Markets
TriMark Publications, Oct 2009, Pages: 244
According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. What’s more, threatening pandemics such as swine flu (H1N1 influenza A virus) are adding significant pressure to already strained healthcare budgets of governments around the world.
This report provides a detailed description of the current infectious diseases drugs market and highlights the existing and developing anti-infective agents used to ameliorate diseases’ afflictions on humankind. Anti-infective agents include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Particular attention is paid to the clinical market segment and the pharmaceutical/biotechnology companies involved in anti-infective agents, with specific emphasis on each company’s sales focus, product portfolio and R&D pipeline. To date, the most successful anti-infective agents target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). A number of exciting novel anti-viral and antibiotic compounds are currently revolutionizing the infectious diseases drugs market, including Truvada and Valtrex, which are anti-HIV and anti-herpes therapies, respectively.
Significant resources are also being dedicated toward hepatitis A (HAV), hepatitis B (HBV) and Staph infections, including MRSA. What’s more, this study will examine the existing and developing anti-infective agents targeted at infectious diseases that continue to devastate developing countries, including: cholera, dengue fever, meningitis, rotavirus, typhoid, yellow fever and onchocerciasis (“river blindness”).
Keywords:
Infectious Diseases, pneumonia, tuberculosis, swine flu, H1N1, influenza A virus, diarrheal, malaria, measles, HIV, AIDS, herpes, HSV-1, HSV-2, hepatitis A, HAV, hepatitis B, HBV, hepatitis C, HVC, Staph, MRSA, cholera, dengue fever, meningitis, rotavirus, typhoid, yellow fever, onchocerciasis, river blindness
Customers who bought this item also bought
Competitor Analysis: Anti-Infective Peptides
The Anti-Infectives Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Commercial Insight: Infectious Diseases Overview
The Global Anti-Infectives Market Outlook to 2011
Stakeholder Opinions: Biologics in Infectious Diseases - Well Defined Target Populations are Key to Commercial Success
China Anti-Cancer Drug Market Report 2008
New Drug Futures: Anti-Infective Chapter
FDA Anti-Infective Drugs Advisory Committee Meeting on CAP Drug Development - Advanced Life Sciences Holdings, Inc., - Earnings Transcript
Anti-Counterfeiting Strategies - Combating Fake Pharmaceuticals
China Anti-Diabetic Drug Market Report 2008
Research Report on Chinese Anti-Tumor Drug Market, 2009
Commercial and Pipeline Insight: Hepatitis B
|
|
|
|
